Stratagene Shares Dive 8.6 Percent After Judge Trebles Damages in Invitrogen IP-Infringement Verdict | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Stratagene were down 8.6 percent, or $.59, at $6.24 in mid-afternoon trading today after a judge ordered the company to pay $16 million in damages to Invitrogen for willfully infringing one of its patents.
 
Separately today, investment bank Robert W. Baird downgraded Stratagene’s stock to ‘Underperform’ from ‘Neutral.’
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.